For investors

The Biotts scientists and inventors team developed the first on the world’s and unique technology that allows transport through the skin hydrophilic, lipophilic, large molecules, proteins and antibodies. MTC-Y technology is a revolution in the global pharmaceutical market. What is more Biotts is the first biotechnology company in Central Europe that creates proprietary preparations and drug formulas based on extracts of natural origin and proprietary carriers of active substances that increase their bioavailability. Patented proprietary carriers of active substances can also be used as a transport system for commonly used oncological, anti-inflammatory and analgesic drugs, increasing their targeted effects by up to 10 times, reducing the drug dose by 10 times and radically minimising the side effects of therapy.

The market

For several years now, the biotechnology market has been steadily showing a high growth rate. Total revenue reached its historically highest level of $139.4 billion in 2016. Expenditure on research and development increased by 12%, to $45.7 billion. Employment in biotechnology companies in the US and Europe increased to over 200,000 people, 14% more than a year before.

Revenues of the biotech sector companies since 2000:

Source: Report “Biotechnology Report Beyond Borders” by EY

Revenues of industry leaders (companies generating at least 500 million USD in revenues) increased by 8% to 122.4 billion USD in 2016, which represents 88% of the revenues of the entire sector. Since 2011, the amount of revenues generated by commercial leaders has doubled from the level of 61 billion USD. At the same time, the number of companies generating the highest revenues in the US and Europe increased from 23 to 27. 2016 was also the sixth consecutive year when the total expenditure on R&D increased.

BIOTTS product market

The market for transdermal drug transport systems

MTC-Y
According to the MARKETSANDMARKETS report “Transdermal Second Delivery System Market – Global Forecast to 2022”, the global market for transdermal drug delivery systems (TDDS) in 2017 amounted to nearly $35.72 billion. By 2024, the TDDS market will be worth $81.46 billion. The average market growth is estimated at a record level of 12.5% per year.

Diabetology

Diabetes type II

MTC-D1 and MTC-S1
According to GlobalData, the global type II diabetes market will grow from USD 48 billion in 2019 at a compound annual growth rate (CAGR) of 6.7% to USD 80.6 billion in 2027.

Based on epidemiological analysis, the number of diagnosed cases of type 2 diabetes is expected to increase from 164.8 million to 206.4 million cases in 2027 in nine major markets (U.S., EU5, Japan, India, and China)

Oncology

Breast cancer

MTC-B7
1 in 8 women in the world is diagnosed with breast cancer and every 29 seconds a new case of breast cancer is confirmed.

In 2012, 1,700,000 women worldwide developed breast cancer. In the same year, 500,000 women died of breast cancer.

Breast cancer is the most common type of cancer, accounting for as much as 21% of detected cases. In Poland, breast cancer is diagnosed in about 17,000 women every year, and over 6,000 women die of breast cancer in Poland annually.

In 2018, the global market for breast cancer medicines was worth $13.4 billion, and in 2021 it will reach $17.2 billion. According to the GlobeNewswire report, the market for oncological drugs for breast cancer by 2025 may even grow to the level of $28 billion.

Skin cancer

MTC-U1
Skin cancer is the most common cancer detected among the young population aged 25-29, with the highest number of cases diagnosed in people over 60 years of age. Skin cancer is detected in 1/34 young men and 1/53 women. Every year, more than 3.8 million people with different skin cancers are diagnosed in the US, while melanoma is detected in more than 76,000 people a year. The annual cost of treating patients with melanoma in the US alone is $2.36 billion.

The Management Board

Paweł Biernat, PhD
CEO & Transdermal Systems Specialist

Co-founder and co-author of BIOTTS patents and therapeutic systems.

Jan Meler, PhD
Director of the Drug Development Department

Co-founder and co-author of BIOTTS patents and therapeutic systems.